Skip to content

An observational study on the efficacy comparison between the dual regimen of voronoxan combined with high-dose amoxicillin and the quadruple regimen of bismuth in eradicating Helicobacter pylori infection

An observational study on the efficacy comparison between the dual regimen of voronoxan combined with high-dose amoxicillin and the quadruple regimen of bismuth in eradicating Helicobacter pylori infection

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2400089354
Enrollment
Unknown
Registered
2024-09-06
Start date
2024-09-09
Completion date
Unknown
Last updated
2024-09-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Helicobacter pylori infection

Interventions

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Determine Helicobacter pylori infection by C13 or C14 breath test or rapid urease test; 2. Vonolasone plus high-dose amoxicillin or Vonolasone plus metronidazole+amoxicillin+bismuth quadruple therapy; 3. The age is between 18 and 75; 4. I have not participated in other research projects at present; 5. Agree to participate in this research topic and sign the informed consent form; 6. Penicillin skin test is negative;

Exclusion criteria

Exclusion criteria: 1. Use antibiotics, PPI, H2 receptor antagonists, bismuth and other drugs in the last month; 2. Lactating or pregnant women; 3. Have serious diseases such as heart, lung, liver and kidney; 4. Suffering from digestive tract tumors and malignant tumors in other parts or chronic diseases in other systems; 5. Have an allergic history to any of the drugs in the scheme (voronin, amoxicillin, metronidazole, bismuth potassium citrate). 6. The above two schemes were not adopted to eradicate Hp.

Design outcomes

Primary

MeasureTime frame
Eradication rate;

Secondary

MeasureTime frame
Medicine compliance; Adverse reaction rate;

Countries

China

Contacts

Public ContactLu Yingying

Shanghai General Hospital

yingying.lu1@shgh.cn+86 186 2158 3036

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026